Get the daily newsletter

FDA votes on the future of Covid-19 vaccinations in the US


Photo by Joshua Sukoff on Unsplash

FDA has updated the authorization of AstraZeneca’s Evusheld vaccine. FDA votes to approve a new bivalent Covid-19 vaccine that combines primary and booster dose.

Where: United States

The Facts

The Food and Drug Administration has updated the Emergency Use Authorization for Evusheld to limit its use as it is “unlikely to be active against certain SARS-CoV-2 variants.”
According to the most recent CDC Nowcast data cited by the FDA, these variants are projected to be responsible for more than 90% of current infections in the U.S.
As such, AstraZeneca’s Evusheld vaccine is not expected to protect recipients from developing COVID-19 if they are exposed to said variants.
The FDA also voted on whether to roll out a two-strain Covid-19 shot that combines both the primary and booster doses currently in use.
Committee members voted 19-2 to approve “a bivalent vaccine with an original strain component and an Omicron variant component.” A general preference was expressed for vaccine coverage of Omicron sublineages BA.4 and BA.5.

Primary Sources

Direct, authoritative source material on this story.

Reference Articles

Articles Citable has ingested related to this story.

Reference Articles

Articles Citable has ingested related to this story.

Media Coverage

Why did we include this story

Most covered story by the media today

of articles referenced this story

Coverage by Media Outlet

Media outlets covering this story along with their positive or negative sentiment toward this story.